MCLN, ANYI, BPAX, MDCE, KERX, GEAR
Our Stocks to Watch today include MedClean Technologies Inc. (OTCBB: MCLN), AnythingIT Inc. (OTCBB: ANYI), BioSante Pharmaceuticals Inc. (NASDAQ: BPAX), Medical Care Technologies Inc. (OTCBB: MDCE), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) and Gear International Inc. (OTC: GEAR).
MEDCLEAN TECHNOLOGIES INCORPORATED (OTCBB: MCLN)
"Up 100.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/MCLN.php
MedClean Technologies, Inc. is a provider of innovative technology and services for the treatment and disposal of regulated medical waste. MedClean's flagship MedClean® Series systems are fully integrated, turnkey technology solutions that enable healthcare providers and medical waste haulers to safely, efficiently, and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste. MedClean was founded in 1997 with corporate headquarters, research and development and distribution facilities now located in Bethlehem, Pennsylvania.
April 10 - MedClean Partners with MedPro Waste Disposal LLC and the IMWTA to Implement Service Program to Customers of Major GPO
Exclusive Program Includes Medical Waste Brokerage Services, Hauling Services, and Billing and Administrative Support Services to more than 100,000 Non-Acute Care GPO Member Facilities
MedClean Technologies (OTCBB: MCLN), the leading provider of technology designed for the efficient treatment and disposal of medical waste and the destruction of confidential documents and related media, today announced it has partnered with MedPro Waste Disposal LLC and the Independent Medical Waste Transporters Association (IMWTA) to implement their first initiative to organize and utilize the IMWTA members extensive services.
The Medical Waste Hauling Program is sponsored by MedClean and powered by MedPro's dedicated account management and sales teams.
Highlights of the program include, but are not limited to:
* Exclusive relationship with a major U.S. based Group Purchasing Organization and their member base of more than 100,000 non-acute care facilities
* Guaranteed customer savings of 20% or more based upon the term of the agreement
* "No Surprise" billing services. All costs of the program are disclosed at the time the Service Agreement is signed and remain fixed for the duration of the Service Agreement
* Utilization of MedPro's dedicated team for the implementation of the program to ensure the program is offered to all members. The campaign includes telemarketing, bid/proposal management to the IMWTA, contract administration, and customer billing services
* Utilization of IMWTA members hauling services to provide local, friendly, and high quality services
* Targeted market represents 10% to 20% of the $3.5 billion dollar medical waste market
"This is a landmark program for the Regulated Medical Waste industry, specifically to the small quantity waste generator (SQG), which typically pays significantly higher prices for hauling services due to the fact that only one entity existed in the market place that had the bandwidth to serve the market," commented David Laky, President and CEO, MedClean Technologies, Inc. "Through the partnerships we have developed, we have been able to identify a target market, develop a savings program for that market, increase the value proposition our GPO partner provides to that market, and most importantly deploy high quality services to the participants. Our partners are committed to the success of this program and have backed that commitment through contracted milestones. Additional goals of the program include enhanced opportunity for ecommerce sales and through tracking waste volumes handled by the IMWTA we will be able to pinpoint key opportunities to place localized medical waste processing centers featuring our MedClean Series equipment."
ABOUT MEDPRO DISPOSAL LLC
MedPro Waste Disposal LLC (MedPro) provides reliable, cost-effective medical waste disposal services to large and small quantity generators of medical waste. At, MedPro, we recognized a need for standardized costs across an industry largely dominated by a single entity. There were too many instances where customers were being charged drastically different prices for the same service. Some industry leaders continue to use this pricing strategy on their own customers, charging similar waste generators not-so-similar prices. In an industry full of regulations, there appeared to be none when it came to reasonable and fair business practices.
MedPro has formed an alliance with MedClean and the IMWTA transporters to provide the safest and most economical destruction of medical waste. Our goal is to ensure that our customers receive the quick, reliable service you have come to expect from your medical waste hauler with the peace of mind that you are not paying more than your neighbor, and that your waste is being properly disposed of.
ANYTHINGIT INCORPORATED (OTCBB: ANYI)
"Up 76.47% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/ANYI.php
AnythingIT, Inc. is a United States Government-GSA contracted, CCR-registered small business vendor with Congressional Recommendation for IT Asset Recovery/Trade-in, Forensic DataScrub (Department of Defense 5220.22M certified), Donation Processing, and EPA E-Waste Disposal services. Entering the 19th year of business, AnythingIT services both the commercial Fortune 500 as well as U.S. Government entities out of facilities nationally and globally.
April 23 - AnythingIT Completes Tenth Year Managing Free E-Waste Recycling and Asset Recovery Program for Fujitsu America Customers
AnythingIT (OTCBB: ANYI), a leading information technology (IT) Asset Recovery and E-Waste handler for government and commercial markets, today announced the completion of its tenth year managing its Free E-Waste Recycling & Asset Recovery Programs for customers of Fujitsu America. As part of the initiative, AnythingIT also offers a separate trade-in program whereby customers have a safe and secure method of selling their outdated or obsolete IT equipment. With these programs, Fujitsu America and AnythingIT are offering end users and resellers a convenient and easy way to dispose of equipment in a clean and "green" way.
AnythingIT, a U.S. Government Contractor for IT Asset Disposition, and Fujitsu have worked together since 2002 and will dispose of the obsolete and non-working IT equipment at no charge.
BIOSANTE PHARMACEUTICALS INCORPORATED (NASDAQ: BPAX)
"Up 56.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/BPAX.php
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at www.biosantepharma.com.
May 8 - BioSante Pharmaceuticals Reports First Quarter Financial Results
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reported on its financial results for the first quarter of 2012 and cash balance as of March 31, 2012.
BioSante’s cash balance as of March 31, 2012 was approximately $49.5 million, compared to a cash balance of approximately $57.3 million on December 31, 2011.
BioSante incurred a net loss of approximately $10.3 million or $(0.09) per share for the quarter ended March 31, 2012, compared to a net loss of $17.3 million or $(0.20) per share for the same period in 2011. The decrease in the net loss was due primarily to lower expenses associated with the clinical development of LibiGel® (testosterone gel).
BioSante’s corporate strategy always has included product development of high value medically-needed pharmaceutical products. In light of the top-line results from the two pivotal LibiGel Phase III efficacy trials, which indicated that LibiGel did not meet its co-primary or secondary endpoints, management continues to assess LibiGel’s path forward and potential alternative strategies to utilize the continuing LibiGel Phase III cardiovascular events and breast cancer safety study. Management also has expanded efforts to explore new product development projects through in-licensing and mergers and acquisitions as well as to develop further the GVAX cancer vaccine portfolio.
The current projected cash burn rate for 2012 is approximately $2.5 million per month, including expenditures related to the ongoing LibiGel safety study. If a decision is made to halt the LibiGel safety study, the monthly cash burn rate will decline to approximately $1.5 million per month, pending other product development and corporate activities.
MEDICAL CARE TECHNOLOGIES INCORPORATED (OTCBB: MDCE)
"Up 42.86% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/MDCE.php
Medical Care Technologies Inc. is traded under the symbol "MDCE" on the OTCBB and is headquartered in Beijing, China. MDCE, through joint ventures or Chinese subsidiaries, develops a network of children's health facilities in the larger urban areas throughout China. Services are geared towards the advancing economic middle-class and upper class Chinese families. Specializing in the care of children between the ages of 3 to 16, MDCE's role is to enhance the overall well-being of the family and community and to expand its pediatric services to include preventative health and wellness education. MDCE, through its children's health facilities, will also distribute a diverse range of industry-leading pharmaceutical and nutraceutical product lines. MDCE's main mission is simple – to become a healthcare service provider leader in children's health.
April 30 - Medical Care Technologies Inc. Receives $10 Million Reserve Equity Financing From AGS Capital Group, LLC
Medical Care Technologies Inc. (OTCBB: MDCE), a growing children's healthcare service provider, is extremely pleased to announce that it has received a Reserve Equity Financing of US$10,000,000 over a term of 4 years.
The Reserve Equity Financing ("REF") with AGS Capital Group, LLC, is a comprehensive financing solution that will provide direct investment capital of up to $10 million without putting undue stress upon the Company's share capital structure. It is an inexpensive and flexible financing strategy in which the Company controls the amount of any advance and its timing – the how and when, therefore, regulating and minimizing any potential impairment to its share structure.
"We believe this funding will provide us with the flexibility needed to expand our business," said Luis Kuo, Chief Operating Officer. "As the demand in China to implement our business model and to expand our children's health centers to other locations has been overwhelming, securing the right financing will give us the ability to manage both the long-term growth of the Company and shareholder value."
Ning Wu, Chief Executive Officer, stated, "We are excited to be entering into a relationship with a strong financial partner. It took research and many months to come to what we believe will turn the tides for Medical Care Technologies Inc. This type of financing will allow us to grow, concentrating our efforts on developing, building and staffing of children's health centers without the constant pressure of financing."
"We believe that there is a tremendous market in China for the services that Medical Care Technologies Inc. provides and see significant growth for the company during the next year," says Allen Silberstein, Chief Investment Officer of AGS Capital Group.
ABOUT AGS CAPITAL GROUP, LLC
AGS Capital Group provides flexible equity financing solutions for growth-stage and mid cap public companies as well as private companies looking to go public. AGS Capital Group invests in public companies around the world listed on most exchanges. AGS Capital Group performs fundamental analysis including credit risk, technical analysis of market trends and industry, evaluation of management team experience and corporate structure evaluation.
KERYX BIOPHARMACEUTICALS INCORPORATED (NASDAQ: KERX)
"Up 15.58% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/KERX.php
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease and cancer. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing KRX-0401 (perifosine), which is in Phase 3 clinical development for multiple myeloma. Keryx is headquartered in New York City.
May 21 - Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced that an abstract highlighting the dose related increases in iron storage parameters as observed in prior clinical trials of Zerenex™ (ferric citrate), has been accepted for poster presentation at the upcoming 49th ERA-EDTA (European Renal Association – European Dialysis and Transplant Association) Congress, taking place May 24-27, 2012, in Paris, France.
The following poster will be presented on Saturday, May 26, 2012, from 9:30am to 10:45am local time:
* A Meta-Analysis of Ferric Citrate for Hyperphosphatemia: The Effects of an Oral Iron-Containing Phosphate Binder on Serum Ferritin and Saturated Transferrin in Hemodialysis Patients (Abstract # SAP534)
Zerenex, the Company's oral, ferric iron-based drug candidate for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis, is currently in Phase 3 clinical development pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. The Zerenex Phase 3 registration program is comprised of an already completed Phase 3 short-term study, and an ongoing Phase 3 long-term study.
Keryx holds a worldwide license (except for certain Asian Pacific countries) to Zerenex (ferric citrate) from Panion & BF Biotech, Inc. The Japanese rights are sublicensed by Keryx to Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.
GOLFGEAR INTERNATIONAL INCORPORATED (OTC: GEAR)
"Up 63.79% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/GEAR.php
GolfGear International, Inc. was originally incorporated in 1996 as a golf equipment company. The Company has recently altered its business strategy to include gold and silver mining, providing financing for gold and silver mining projects, and precious metals processing and refining.
May 20 - Gear International, Inc. Updates Financial Statements, Shows Increased Value and Progress of Business Model
Gear International, Inc. (OTC: GEAR) released financial statements demonstrating significant improvement in asset value and cash on balance from 2010 to the current fiscal year. Complemented by a series of asset acquisitions and joint venture agreements on several mining claims, the underlying company financials suggest a fundamental enhancement of shareholder value could soon be realized. GEAR has added 5 mining claims and improved its cash reserves. Additionally, GEAR management is anticipating a market correction in the value of the company's stock after successfully eliminating a hostile shareholder from the float.
GEAR's value to its stockholders continues to exhibit transformational potential. During the period between December 31st 2010 and December 31st 2011, GEAR's stockholder equity transformed from a negative value to over 7 million dollars with minimal public activity or wealth generating capacity. In 2012, management's substantial improved GEAR's brand awareness, activities, and asset claims.
GEAR president Dale Geck affirms: "The industry averages for mining companies possessing producing assets suggest that current and near term shareholders could be observing exponentially increased value within the next few quarters. Company due diligence was unable to yield evidence of a publicly traded company with ownership of a producing gold mine maintaining market capitalization of less than 500 million USD; GEAR has several projects with historical reserve volumes exceeding that number. Over the next 120 days as we register those reserves with today's leading standards, current shareholder values could be rendered obsolete."